Search
Poloxalene
go.drugbank.com/drugs/DB11451InvestigationalVet approvedIt belongs to the family of Epoxides. These are compounds containing a cyclic ether with three ring atoms (one oxygen and two carbon atoms).
Collagenase clostridium histolyticum
go.drugbank.com/drugs/DB00048ApprovedInvestigational[L14882] The topical formulation is used for the debridement of necrotic tissue due to burns or chronic ulcers. … [L14872] Also known as Qwo, this injection is the first approved injectable treatment for cellulite and was developed by Endo International.[L14892]
Products: QwoPretomanid
go.drugbank.com/drugs/DB05154ApprovedInvestigationalResearch in recent years has been geared toward the development of novel therapies that target persistent forms of this disease, which have shown resistance to standard therapy regimens. … Persistent forms of tuberculosis (TB) have proven to be a major cause of global morbidity and mortality and a cause for significant concern.
Somapacitan
go.drugbank.com/drugs/DB15093ApprovedInvestigationalSomapacitan, also known as NNC0195-0092,[A219136] is a growth hormone analog indicated to treat adults with growth hormone deficiency. … [A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily.
Efavirenz
go.drugbank.com/drugs/DB00625ApprovedInvestigationalEfavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with
Mixtures: Symfi Lo, Symfi LoSynonyms: (S)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one, 6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-onePeginterferon beta-1a
go.drugbank.com/drugs/DB09122ApprovedInvestigational[L5801] MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men. … Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life.
Siltuximab
go.drugbank.com/drugs/DB09036ApprovedInvestigationalIts use is indicated for the treatment of adult patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. … Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6).
Naltrexone
go.drugbank.com/drugs/DB00704ApprovedInvestigationalVet approvedDerivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addi...
Synonyms: 17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one, 17-(Cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-oneCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeFostamatinib
go.drugbank.com/drugs/DB12010ApprovedInvestigationalRecently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK
Lithium carbonate
go.drugbank.com/drugs/DB14509ApprovedInvestigationalLithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. … Lithium has been used to treat manic episodes since the 19th century[A176642]. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843].
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome